HomeAI · summaries
Storia in 5 fonti
Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom
Eli Lilly reported $98 million in second-quarter sales fo | Eli Lilly reported $98 million in second-quarter sales for Foundayo, its newly launched oral GLP-1 treatment, lagging far behind rival Novo Nordisk's Wegovy pill.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
independent.co.uk
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
- ·
endpoints.news
Novo vs. Lilly: Q2's cardiometabolic grudge match
Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.
